Evolus (NASDAQ:EOLS) Reaches New 1-Year High – Here’s What Happened

Evolus, Inc. (NASDAQ:EOLS)’s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $8.00 and last traded at $7.9980, with a volume of 558070 shares traded. The stock had previously closed at $7.57.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EOLS. Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a report on Saturday. Finally, BTIG Research reiterated a “buy” rating and issued a $13.00 target price on shares of Evolus in a report on Wednesday, June 17th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.50.

Evolus Trading Up 5.5%

The company has a market cap of $527.74 million, a price-to-earnings ratio of -15.37 and a beta of 1.35. The business has a fifty day moving average price of $6.52 and a two-hundred day moving average price of $5.56.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Evolus by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after buying an additional 1,838 shares during the period. Millennium Management LLC raised its holdings in shares of Evolus by 1.7% during the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock worth $16,746,000 after acquiring an additional 23,605 shares in the last quarter. Jones Financial Companies Lllp acquired a new stake in Evolus during the first quarter valued at $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Evolus by 36.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock valued at $1,883,000 after purchasing an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in Evolus by 484.8% in the first quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock valued at $841,000 after purchasing an additional 57,987 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.